(Total Views: 438)
Posted On: 09/22/2020 10:09:03 PM
Post# of 36566
Hello all. I am a relatively new investor (January 2020) but have worked with Health Canada in my past. I can attest that the Canadian Govt would not be considering The NGIO vaccine as an option without knowing the results of the peptides. Their ministry of health values clinical-results-first everything else second.
The process in Canada is known as the most stringent for device and drug standards in the entire world, so it is very good to see that GNBT/NGIO has been selected to a short list there. Furthermore, if GNBT/NGIO knows it’s peptides work they are likely very busy proposing to multiple entities right now both in govt sectors and possibly private. All of these talks would likely be covered by an NDA until an MOU or a signed agreement. They will make what is public, public when able, but I personally find solace in the BK agreement as representing a $150MM floor for Generex/NGIO. Just my $0.02
The process in Canada is known as the most stringent for device and drug standards in the entire world, so it is very good to see that GNBT/NGIO has been selected to a short list there. Furthermore, if GNBT/NGIO knows it’s peptides work they are likely very busy proposing to multiple entities right now both in govt sectors and possibly private. All of these talks would likely be covered by an NDA until an MOU or a signed agreement. They will make what is public, public when able, but I personally find solace in the BK agreement as representing a $150MM floor for Generex/NGIO. Just my $0.02
(8)
(0)
